SALT LAKE CITY and TORONTO and MONTRÉAL, May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today ...
After a year defined by pipeline cuts, the departure of its CEO and layoffs, Exscientia will merge into Recursion, creating one company that has 10 clinical readouts to look forward to over the next ...
Scientists in Spain have implemented recursive least squares (RLS) algorithms for anomaly detection in PV systems and have found they can provide “more realistic and meaningful assessment” than ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Hosted on MSN
Recursion outlines extended cash runway into early 2028 as platform efficiency accelerates
Najat Khan, CEO, opened by stating that Recursion is at an important inflection point, harnessing its integrated AI-driven platform to "translate insights into evidence; evidence that this platform, ...
Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...
Recursion stands out as a pure play in AI-powered biotech, using machine learning algorithms to accelerate drug research and development (R&D). The company's BioHive-2 supercomputer, powered by Nvidia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results